Haplo-PBSC+Cord vs haplo-PBSC+BM for hematological malignancies undergoing allo-HSCT

A comparative study of haploidentical transplantation supported by third-party cord blood and haploidentical transplantation in hematological malignancies

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049270

Enrollment

Unknown

Registered

2021-07-28

Start date

2021-07-28

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignancy

Interventions

Haplo-PBSC+cord:PBSC+cord

Haplo-PBSC+BM:PBSC+BM

Eligibility

Sex/Gender

All

Age

14 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 14 to 65 years; 2. Hematological malignancies undergoing haplo-HSCT.

Exclusion criteria

Exclusion criteria: 1.Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure); 2.Patients with any conditions not suitable for the trial (investigators' decision).

Design outcomes

Primary

Measure	Time frame
One-year cumulative event-free survival;	—

Secondary

Measure	Time frame
Hematopoietic reconstruction;Graft versus host disease;Cytomegalovirus and EB virus infection;Cumulative incidence of relapse;Transplant related complications;Overall survival;	—

Countries

China

Contacts

Public ContactQifa Liu

Department of Hematology, Nanfang Hospital, Southern Medical University

liuqifa628@163.com+86 13602791429

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026